Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 5;12:828439. doi: 10.3389/fcimb.2022.828439

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Madhvi, Mishra, Chegou and Baker

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Comparison of mRNA expression (fold changes) for in vitro protocol [M. smegmatis, M. bovis BCG and M. tb R179] for (A) IFIT1, (B) IFIT2 and (C) IFIT3. We also compared mRNA expression of IFIT1,(D), IFIT2 (E) and IFIT3 (F) in clinical cohort across HC, TB and LTBI group. We observed significantly higher expression of IFIT1, IFIT2 and IFIT3 in LTBI cases as compared to HC and TB. This indicates role of IFITs in mycobacterial containment in LTBI cases. For in vitro protocol, we also observed higher expression of IFITs in species with lower pathogenicity. BCG, Bacillus Calmette-Guerin; HC, healthy control; IFITs, interferon-induced protein with tetratricopeptides; LTBI, latent tuberculosis infection; TB, tuberculosis Supplementary Figures 7A–C depicts the mRNA fold changes of different genes (20 other genes) across the Clinical and in vitro protocols. ****p < 0.0001.